Shallaki in Ayurveda: Properties & Everyday Use

What it is

Shallaki is the Ayurvedic name for Boswellia serrata Roxb. ex Colebr., a tree in the frankincense family (Burseraceae) native to dry regions of the Indian subcontinent (PMC trial paper). The medicinal part is the oleo-gum resin that exudes from the bark: a substance also known as salai guggul. Its best-studied constituents are the boswellic acids, a group of pentacyclic triterpenes; the most pharmacologically notable is 3-acetyl-11-keto-β-boswellic acid (AKBA), which potently inhibits 5-lipoxygenase, an enzyme in the inflammatory leukotriene pathway (same trial paper). Because the resin's composition varies, clinical trials have used standardized extracts with defined boswellic-acid content: a detail that matters when interpreting the results.

Classical properties

• Taste (rasa): astringent (Kashaya), bitter (Tikta)
• Qualities (guna): light (Laghu), dry (Ruksha)
• Potency (virya): cooling (Sheeta)
• After digestion (vipaka): pungent (Katu)
• Doshas: traditionally said to settle Pitta and Kapha; may increase Vata

Traditional use

In Ayurveda, shallaki's gum resin is a classical herb of the joints, described for sandhivata, the Ayurvedic correlate of osteoarthritis, and credited in the classics with shothahara (anti-inflammatory) and vedanasthapana (pain-relieving) properties and potent vata-kaphahara activity. The clinical evaluation cites Bhava Prakasha for this traditional profile (Gupta et al., AYU, via PMC). Traditional practice also extends its use to other painful and inflammatory conditions. These are traditional descriptions, not clinical proof; the research is assessed separately below.

What research has looked at

Knee osteoarthritis — randomized trials

The best-studied indication by far is knee osteoarthritis. The landmark trial is Kimmatkar et al. (2003, Phytomedicine): a randomized, double-blind, placebo-controlled crossover study in 30 knee-OA patients using WokVel, a standardized extract with defined boswellic-acid content, for 8 weeks. All treated patients reported decreased knee pain, increased knee flexion, and greater walking distance and stair-climbing ability, with symptoms returning after withdrawal; the placebo group showed no significant improvement (tabulated in PMC; trial description). It is a small, single-center, industry-supplied trial: encouraging but not definitive on its own.

Subsequent trials tested enriched extracts: Sengupta et al. (2008) evaluated 5-Loxin (an AKBA-enriched extract) at two dose levels for 90 days in 75 patients, reporting significant pain and function improvements within 7 days. Sengupta et al. (2010) and Vishal et al. (2011) tested Aflapin (a synergistic composition) (trial characteristics tabulated in PMC). Sontakke et al. (2007) ran a 180-day open randomized comparison of Boswellia extract against the COX-2 inhibitor valdecoxib (tabulated in PMC); this does not make it a substitute for medicine. Never use it in place of, or alongside, prescribed medicine without your doctor.

Knee osteoarthritis — meta-analyses

The trials have been pooled twice. Yu et al. (2020, BMC Complementary Medicine and Therapies) meta-analyzed 7 RCTs with 545 OA patients: versus control, Boswellia relieved pain (VAS weighted mean difference −8.33; WOMAC pain −14.22) and stiffness (WOMAC stiffness −10.04) and improved joint function (WOMAC function −10.75; Lequesne index −2.27), all statistically significant, with a recommended treatment duration of at least 4 weeks (PMC). A 2025 systematic review and network meta-analysis of 20 RCTs (1,633 participants) found that modified Boswellia formulations significantly improved WOMAC pain, stiffness, and knee function, with no significant differences in adverse events across comparisons (PubMed).

Quality caveats — read these before buying anything

The signal is real but fragile: only about 545 patients across the 7 trials in the 2020 pooling; most trials were short (4–12 weeks), small, and single-center. Several used proprietary enriched extracts (5-Loxin, Aflapin) whose results do not automatically generalize to generic resin powder; and a characteristics table of the included trials flags industry sponsorship across the board (PMC). The evidence supports shallaki as a reasonable short-term option for knee-OA symptoms: not as a proven disease-modifying treatment, and not as proof that any retail product works.

Inflammatory bowel disease (contested, preliminary)

Three small clinical trials reported symptom improvement in ulcerative colitis and Crohn's disease with boswellia. However, a subsequent controlled study in mouse colitis models found boswellia ineffective, observed hepatotoxic effects (hepatomegaly, steatosis) at higher doses, and warned about "prolonged and uncontrolled intake of boswellia as an herbal supplement" (American Journal of Physiology–GI, 2005). The IBD evidence is therefore preliminary and actively contested: it should not be presented as established.

Safety notes

• A note on the liver. The NIDDK's LiverTox database states that Boswellia serrata extracts "have not been linked to serum aminotransferase elevations during treatment or to instances of clinically apparent acute liver injury" (LiverTox via PubMed Bookshelf). This is human clinical-trial experience; a mouse study did observe hepatomegaly and steatosis at higher doses, which has not been replicated in humans (AJP-GI, 2005).
• Common side effects. Mostly mild gastrointestinal symptoms, nausea, diarrhea, bloating, reported at rates similar to placebo in the meta-analyzed trials (PubMed network meta-analysis).
• During pregnancy and breastfeeding. It is best avoided: safety has not been established in pregnancy or lactation, and there are no adequate human data.
• Medications and surgery. If you take anticoagulant or antiplatelet medicines, immunosuppressants, or have surgery scheduled, discuss shallaki with your clinician first: interaction data are limited and this is a pharmacologically active anti-inflammatory.
• Allergy. Rare allergic reactions are possible; people sensitive to tree resins should be cautious.

FAQs

Does shallaki help with knee arthritis?

The best available evidence says it can reduce symptoms. A 2020 meta-analysis of 7 RCTs (545 patients) found significant improvements in pain, stiffness, and function versus control, and a 2025 network meta-analysis of 20 RCTs confirmed the signal (PMC; PubMed). But the trials were small, short, and mostly industry-linked, so treat this as promising rather than proven: and it is symptom relief, not cartilage repair.

How long does shallaki take to work?

In trials, outcomes were measured after 4–12 weeks of daily use, and the 2020 meta-analysis recommends at least 4 weeks before judging effect (PMC). One enriched-extract trial reported improvements within 7 days, but that was a single small study of a proprietary formulation (PMC).

What dose of Boswellia was used in studies?

Swastik does not suggest amounts. The right amount depends on the person, the preparation and the product, so check with a qualified Ayurvedic practitioner or your doctor before taking any herb.

Is shallaki safe for the liver?

Human trial data are reassuring: the NIDDK's LiverTox database records no link between Boswellia serrata extracts and liver enzyme elevations or acute liver injury (LiverTox). A mouse study did find liver effects at high doses, which has not been seen in human trials: another reason to avoid large amounts.

Can I take shallaki with blood thinners?

Be cautious and ask your clinician first. Interaction data are limited, and shallaki is a pharmacologically active anti-inflammatory, so combining it with anticoagulant or antiplatelet medicines without medical supervision is not advisable. The same applies before scheduled surgery.

Sources

• Yu G et al. "Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis." BMC Complementary Medicine and Therapies. 2020 (7 RCTs, 545 patients) — PMC · PMC7368679
• "Evaluating the efficacy and safety of Curcuma longa, Boswellia serrata, and their mixed formulation in treating knee osteoarthritis: a systematic review and network meta-analysis." Complement Ther Med. 2025 (20 RCTs, 1,633 participants) — PubMed · PMID 41082950
• "A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee" (trial tabulation incl. Kimmatkar 2003; Sontakke 2007) — PMC · PMC6681146
• "Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis" (trial characteristics table, sponsorship data) — PMC · PMC6131088
• "Efficacy of Boswellia serrata Extract and/or an Omega-3-Based Product for Improving Pain and Function in People Older Than 40 Years with Persistent Knee Pain" (AKBA/5-LOX mechanism) — PMC · PMC10490338
• NIDDK LiverTox — "Boswellia Serrata" (Bookshelf NBK563692): PubMed · PMID 33151656
• Kiela PR et al. "Effects of Boswellia serrata in mouse models of chemically induced colitis." Am J Physiol Gastrointest Liver Physiol. 2005 (animal hepatotoxicity at high doses; contested IBD evidence) — journals.physiology.org
• Gupta PK et al. "Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis)." AYU. 2011 (randomized single-blind trial, n=56, traditional-use background; gum resin ~43% boswellic acids) — PMC · PMC3361921
• "Boswellia as an anti-inflammatory" (Kimmatkar 2003 trial description) — thefreelibrary.com

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.